Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation. (September 2015)

• Record Type: Journal Article
• Authors: Li, Hui; Guo, Lei; Huang, Aixue; Xu, Hua; Liu, Xuemei; Ding, Hongmei; Dong, Jie; Li, Jie; Wang, Chaonan; Su, Xueting; Ge, Xingfeng; Sun, Leqiao; Bai, Chenjun; Shen, Xuelian; Fang, Tao; Li, Zhanghua; Zhou, Yong; Zhan, Linsheng; Li, Shaohua; Xie, Jianwei; Shao, Ningsheng
• Is Part Of: Biomaterials. Volume 63(2015)
• Page Start: 168
• Page End: 176
• Publication Date: 2015-09
• Subjects: Tumor cells -- SELEX -- Aptamer -- Heterogeneous nuclear ribonucleoprotein A2/B1 -- Nanoparticles; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2015.06.013
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: In this study, we further investigated a previously developed aptamer targeting ROS 17/2.8 (rat osteosarcoma) cells. We found that this C6-8 aptamer specifically binds to heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 and that it specifically labeled multiple tumor-cell lines as effectively as hnRNP A2/B1 monoclonal antibodies. When conjugated with fluorescent carbon nanodots (CDots) it could freely enter multiple living tumor cell lines (HepG2, MCF-7, H1299, and HeLa), whose growth it inhibited by targeting hnRNP A2/B1. Similar inhibitory effects were observed when the GFP-HepG2 hepatocarcinoma cells treated with C6-8-conjugated CDots were implanted in nude mice. Our work provides a new aptamer for targeting/labeling multiple tumor cell types, and its nanoparticle conjugates bring further advantages that increase its potential for use in cancer diagnosis and therapy.